GlassVC

Lilly Asia Ventures

Venture capital firm · Founded 2008 · Shanghai, China

Lilly Asia Ventures (LAV) originated as Eli Lilly's venture arm in Asia in 2008 and is now an independent global healthcare investment firm investing from start-up to commercialization stage in life science and healthcare companies, headquartered in Shanghai with offices in the Bay Area.

Tier 1Basis: No sourced AUM, latest fund >= $250M, or documented unicorn+ hit in fetched sources; verifiably real and active independent healthcare investor per the fetched financing article.

Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.

This profile is unclaimed. Built from public sources. If you're a partner or employee at Lilly Asia Ventures, you can claim it.

Claim this profileHow claiming works

Key numbers

Assets under management

$4.3B

Latest fund

LAV Fund VII ($700M hard cap, closed 2025)

Funds

7

Check size

Not publicly disclosed

LAST CHECKED NOV 2026

Stages

SeedSeries ASeries B

Sectors

PharmaceuticalsHuman TherapeuticsMedical DevicesDiagnostics

FIGURES ARE AS PUBLISHED IN THE CATALOG RECORD 1 · PER-FIGURE AS-OF DATES ARE NOT YET IN THE CATALOG

Track record

Outcomes are recorded from public sources and attributed to the firm, not to individual partners. Shutdowns and write-offs are an ordinary part of venture investing; inclusion here is a record, not a judgment.

Hits

Track record

No outcomes recorded yet from public sources.

Misses

Track record

No outcomes recorded yet from public sources.

Partners 2

  • Fei Chen

    Managing Partner

    Board seats

    No public record
  • Yi Shi
    Yi Shi

    Managing Partner

    Board seats

    No public record

Reputation 2

Contact

Published sources only

Published contact

No contact details published by this firm.

GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.

Suggest a source

What founders say

Founder-submitted · Verified identity and relationship

No founder reviews yet

Be the first founder to share your experience with Lilly Asia Ventures. Reviews come from founders whose identity and relationship have been verified.

Write the first review

Methodology

Tier basis — No sourced AUM, latest fund >= $250M, or documented unicorn+ hit in fetched sources; verifiably real and active independent healthcare investor per the fetched financing article. Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.

Figures are shown as published; conflicting figures are never averaged. Review dimension scores appear only once three founders have reviewed this firm; profiles below that threshold do not appear in rated lists.

The catalog does not yet carry per-figure citations or as-of dates: every figure on this page traces to the catalog record listed below, and that limit is stated rather than papered over. Corrections with a source: Suggest a correction.

Source record 1

  1. [1]

    DATABASE · GlassVC catalog — Catalog record for Lilly Asia Ventures — provenance: GlassVC catalog census, November 2026

    CATALOG SOURCE FIELD · LAST CHECKED NOV 2026

    ↩ cites: AUM · Check size · Founded · HQ · Stages · Sectors · Funds · Reputation

PROFILE BUILT FROM PUBLIC SOURCES · 1 CATALOG SOURCE · LAST CHECKED NOV 2026